Diabetes care in the U.S. and Canada

Area of Science:

• Endocrinology
• Clinical Research
• Public Health

Background:

• Type 1 diabetes management requires consistent glycemic control.
• Healthcare delivery systems may influence patient outcomes.
• The Diabetes Control and Complications Trial (DCCT) provided a unique dataset for comparative analysis.

Purpose of the Study:

• To compare glycemic control (HbA1c levels) in type 1 diabetes patients treated in the U.S. versus Canada.
• To determine if differences in healthcare delivery impact glycemic control outcomes.
• To analyze data from a large, multicenter randomized clinical trial.

Main Methods:

• Analysis of data from the DCCT, a large multicenter randomized clinical trial.
• Categorization of patients based on treatment location: U.S. (n=2,604) and Canada (n=245).
• Comparison of HbA1c levels before and after adjustment for demographic, lifestyle, and clinical predictors.

Main Results:

• Baseline HbA1c levels were virtually identical between U.S. and Canadian patients (8.9% vs. 9.0%).
• Adjusted analyses also showed similar HbA1c levels (9.0% vs. 9.2%).
• Entry rates into the trial and glycemic control on conventional care were comparable between countries.

Conclusions:

• Healthcare delivery patterns in the U.S. and Canada did not result in significant differences in glycemic control for type 1 diabetes patients.
• The findings suggest that factors beyond healthcare system variations may be more critical for glycemic control in this population.
• Results from a large randomized trial indicate consistent outcomes across different healthcare settings.